Furthermore, SC-43 reduces liver fibrosis in both hepatotoxic and cholestatic fibrosis mouse models, indicating that the SHP-1 agonist is a potential target for antifibrotic drug discovery. Here, NR0B2 is linked to Hepatic fibrosis.